GGrantIndex
← Leaderboards

Wanpen Vongpatanasin

University Of Texas Sw Med Ctr/Dallas

$14,734,948
Attributed
$29,515,002
Total exposure
9
Grants
5
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $4.5M · FY200525
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$29,515,002 · 9

By mechanism

R01$23,189,235 · 6
R33$4,956,317 · 1
R61$796,575 · 1
K23$572,875 · 1

Top collaborators

Most similar at University Of Texas Sw Med Ctr/Dallas

Same institution · by research overlap

Others in their field

Top investigators on “Hypertension

Research focus

HypertensionAlzheimer&AposBlood PressureRestPreventRandomizedBrainMagnetic Resonance ImagingDementiaImpaired CognitionAttenuatedEnrollmentParticipantAntihypertensive AgentsElderlyRodentCardiovascular SystemCerebrospinal FluidChronicChronic Kidney FailureClinical PracticeRisk FactorsPerfusionS Disease

Grant awards (39)

Impact of Intensive Treatment of Systolic Blood Pressure on Brain Perfusion, Amyloid and Tau in Older Adults (IPAT-study)$2,316,231
R01 · FY2025 · AG
Impact of Dietary Phosphate Excess on Exercise Capacity and Visceral Adiposity$805,115
R01 · FY2025 · HL · contact PI
Impact of Intensive Treatment of Systolic Blood Pressure on Brain Perfusion, Amyloid and Tau in Older Adults (IPAT-study)$2,372,741
R01 · FY2024 · AG
Preventing Cognitive Decline by Reducing BP Target Trial (PCOT)$1,238,148
R33 · FY2024 · AG
Impact of Dietary Phosphate Excess on Exercise Capacity and Visceral Adiposity$789,088
R01 · FY2024 · HL · contact PI
Impact of Intensive Treatment of Systolic Blood Pressure on Brain Perfusion, Amyloid and Tau in Older Adults (IPAT-study)$69,318
R01 · FY2024 · AG
Impact of Intensive Treatment of Systolic Blood Pressure on Brain Perfusion, Amyloid and Tau in Older Adults (IPAT-study)$2,291,354
R01 · FY2023 · AG
Preventing Cognitive Decline by Reducing BP Target Trial (PCOT)$1,238,148
R33 · FY2023 · AG
Impact of Dietary Phosphate Excess on Exercise Capacity and Visceral Adiposity$805,268
R01 · FY2023 · HL · contact PI
Diversity Supplement to "Impact of Intensive Treatment of Systolic Blood Pressure on Brain Perfusion, Amyloid and Tau in Older Adults (IPAT-study)"$69,274
R01 · FY2023 · AG
Impact of Intensive Treatment of Systolic Blood Pressure on Brain Perfusion, Amyloid and Tau in Older Adults (IPAT-study)$2,369,453
R01 · FY2022 · AG
Preventing Cognitive Decline by Reducing BP Target Trial (PCOT)$1,238,148
R33 · FY2022 · AG
Impact of Dietary Phosphate Excess on Exercise Capacity and Visceral Adiposity$805,342
R01 · FY2022 · HL · contact PI
Preventing Cognitive Decline by Reducing BP Target Trial (PCOT)$1,241,873
R33 · FY2021 · AG
Hypertension, intracranial pulsatility and brain A-beta accumulation in older adults$743,929
R01 · FY2021 · AG
Preventing Cognitive Decline by Reducing BP Target Trial (PCOT)$796,575
R61 · FY2020 · AG
Preventing Hypertension and Sympathetic Overactivation by Targeting Phosphate$792,454
R01 · FY2020 · HL · contact PI
Hypertension, intracranial pulsatility and brain A-beta accumulation in older adults$672,027
R01 · FY2020 · AG
Diversity Supplement to "Hypertension, intracranial pulsatility and brain Aβ accumulation in older adults"$71,969
R01 · FY2020 · AG
Preventing Hypertension and Sympathetic Overactivation by Targeting Phosphate$792,454
R01 · FY2019 · HL · contact PI
Hypertension, intracranial pulsatility and brain A-beta accumulation in older adults$694,725
R01 · FY2019 · AG
Preventing Hypertension and Sympathetic Overactivation by Targeting Phosphate$792,454
R01 · FY2018 · HL · contact PI
Hypertension, intracranial pulsatility and brain A-beta accumulation in older adults$694,766
R01 · FY2018 · AG
Preventing Hypertension and Sympathetic Overactivation by Targeting Phosphate$792,454
R01 · FY2017 · HL · contact PI
Hypertension, intracranial pulsatility and brain A-beta accumulation in older adults$708,654
R01 · FY2017 · AG
The Role of Aldosterone on Augmented Exercise Pressor Reflex in Hypertension$550,995
R01 · FY2016 · HL · contact PI
The Role of Aldosterone on Augmented Exercise Pressor Reflex in Hypertension$542,731
R01 · FY2015 · HL · contact PI
The Role of Aldosterone on Augmented Exercise Pressor Reflex in Hypertension$539,975
R01 · FY2014 · HL · contact PI
The Role of Aldosterone on Augmented Exercise Pressor Reflex in Hypertension$550,995
R01 · FY2013 · HL · contact PI
Neural Mechanism of Thiazide-Induced Insulin Resistance$369,790
R01 · FY2008 · HL · contact PI
Neural Mechanism of Thiazide-Induced Insulin Resistance$369,790
R01 · FY2007 · HL · contact PI
Neural Mechanism of Thiazide-Induced Insulin Resistance$402,324
R01 · FY2006 · HL · contact PI
POSTMENOPAUSAL HORMONAL REPLACEMENT THERAPY$104,760
K23 · FY2006 · RR · contact PI
Neural Mechanism of Thiazide-Induced Insulin Resistance$390,000
R01 · FY2005 · HL
POSTMENOPAUSAL HORMONAL REPLACEMENT THERAPY$104,760
K23 · FY2005 · RR
Neural Mechanism of Thiazide-Induced Insulin Resistance$23,565
R01 · FY2005 · HL
POSTMENOPAUSAL HORMONAL REPLACEMENT THERAPY$114,955
K23 · FY2004 · RR
POSTMENOPAUSAL HORMONAL REPLACEMENT THERAPY$124,200
K23 · FY2003 · RR
POSTMENOPAUSAL HORMONAL REPLACEMENT THERAPY$124,200
K23 · FY2002 · RR